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Abstract
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple
myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer
(NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of
action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and
inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with
immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in
treating MM.
Background
The paradigm of multiple myeloma (MM) therapy has
changed dramatically in the past two decades. Immuno-
modulatory drugs (IMiDs) including thalidomide and
lenalidomide and proteasome inhibitors (PIs) such as bor-
tezomib and carfilzomib emerged as novel agents with
high efficacy [1–3] and greatly improved overall survival
(OS) of patients with MM [4]. Despite these significant
advances, most patients still relapse and eventually be-
come treatment-resistant. The median OS of patients with
disease double refractory to thalidomide/lenalidomide and
bortezomib was only 9 months [5]. Recently, a plethora of
new agents have emerged as effective therapies, including
new generation of PIs (carfilzomib, ixazomib) and IMiD
(pomalidomide), histone deacetylase inhibitors (panobino-
stat, vorinostat), and monoclonal antibodies (daratumu-
mab, elotuzumab), among others, which will hopefully
further improve MM treatment outcomes [6]. While the
CD20 antibody rituximab plays a pivotal role in lymph-
oma treatment, efficacious monoclonal antibodies have
been long awaited in MM. In November of 2015, the US
Food and Drug Administration (FDA) approved the CD38
antibody daratumumab and SLAMF7 antibody elotuzu-
mab for the treatment of MM. In this article, we review
the development and mechanisms of action of elotuzumab
and summarize available data from preclinical and clinical
studies.
SLAMF7 as a therapeutic target in MM
In an attempt to identify potential new therapeutic tar-
gets in MM, Hsi and colleagues [7] first took a subtract-
ive hybridization approach to subtract naïve B cell
complementary DNA (cDNA) from the memory B cell
and plasma cell cDNA library. The remaining genes that
were selectively expressed in plasma cells were screened
for structural/functional classification and the potential
for cell surface localization. SLAMF7 was one of the
genes identified to be highly expressed in plasma cells
and to encode a cell-surface protein against which anti-
bodies could potentially be developed.
SLAMF7, also known as CS1 (CD2 subunit 1), belongs
to the signaling lymphocytic activation molecule
(SLAM) family of cell surface receptors that are import-
ant for immunomodulation [8, 9]. It was previously rec-
ognized as a NK cell surface receptor that was critical
for NK cell activation [10–12]. Gene expression profiling
revealed that SLAMF7 expression was restricted to leu-
kocytes, primarily plasma cells, and NK cells, and absent
in other normal tissues [7]. In addition, SLAMF7 was
highly expressed in plasma cells from healthy donors,
patients with monoclonal gammopathy of undetermined
significance (MGUS), smoldering multiple myeloma
(SMM), and MM regardless of molecular subtype [7].
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Most SLAM family receptors, including SLAMF7, are
self-ligands [8, 9]. Upon receptor engagement, the pres-
ence or absence of adaptor protein in the cell dictates
stimulatory or inhibitory effect, respectively [8]. While
most SLAM family receptors use SLAM-associated pro-
tein (SAP) and EWSFli1-activated transcript-2 (EAT-2)
as adaptors, it appears that SLAMF7 only recruits EAT-
2 [8, 9]. In NK cells, SLAMF7 interacts with EAT-2 and
activates PI3K and PLC-γ signaling pathways, thereby
exerts a positive effect on NK cell function [9, 12]. In
the absence of EAT-2, SLAMF7 mediates an inhibitory
effect [8]. Although plasma cells do not express EAT-2,
SLAMF7 may utilize other mechanisms to promote
myeloma cell growth and survival. Studies have shown
that SLAMF7-mediated signaling is important for the
interaction between myeloma cells and their adhesion to
bone marrow stromal cells (BMSCs) and can activate
ERK1/2, STAT3, and AKT pathways to promote survival
[13, 14]. The expression profile, cell surface localization,
and the cellular functions make SLAMF7 an excellent
therapeutic target in MM.
Elotuzumab development and preclinical studies
in MM
Hsi and colleagues [7] initially developed two mouse
monoclonal antibodies, MuLuc63 (IgG2a) and
MuLuc90 (IgG2b), that recognize the extracellular do-
main of SLAMF7. Both antibodies exhibited in vivo
anti-myeloma activity in a L363 xenograft model. Be-
cause MuLuc63 was significantly more potent, it was
selected for humanization [15]. HuLuc63, the fully hu-
manized version of MuLuc63, exhibited significant
anti-tumor activity in L363, OPM2, and MM1S xeno-
graft models [7, 13, 15]. This antibody was later named
elotuzumab.
The mechanisms of action of elotuzumab include me-
diating antibody-dependent cell-mediated cytotoxicity
(ADCC) [7, 13], enhancing NK cell cytotoxicity [16],
and disrupting MM cell adhesion to BMSC [13] (Fig. 1).
In vitro ADCC studies showed that elotuzumab in-
duced MM cell lysis by peripheral blood mononuclear
cells (PBMCs) [13] and autologous or allogeneic NK
cells [7]. Depletion of NK cells from PBMCs [13] or
Fig. 1 The mechanisms of action of elotuzumab. Upper left, elotuzumab binds SLAMF7 on MM cells, and its Fc fragment is then bound by CD16
on NK cells, mediating ADCC. Upper right, elotuzumab binds SLAMF7 on NK cells, directly enhancing its cytotoxicity. Bottom right, elotuzumab
binds SLAMF7 on MM cells, inhibiting its interaction with BMSCs. NK cell natural killer cell; MM cell multiple myeloma cell; BMSC bone marrow
stromal cell; ADCC antibody-dependent cellular cytotoxicity
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blocking the Fc receptor (CD16) on NK cells [7] signifi-
cantly inhibited the ADCC activity. In the OPM2 xeno-
graft model, altering the HuLuc63 affinity with CD16
affected its anti-myeloma activity accordingly, and de-
pletion or suppressing the function of host NK cells
also abolished its anti-myeloma activity. These studies
suggest that NK cells are the dominant effectors that
mediate elotuzumab-induced ADCC against MM cells.
Collins et al. demonstrated that elotuzumab can also
bind SLAMF7 on NK cells and enhance its cytotoxicity
towards MM cells in an ADCC-independent manner
[16]. Elotuzumab, as well as its G2M3 variant with de-
fective CD16 binding, increased CD69 expression, IFN-
γ production, and granzyme B (GrB) secretion of NK
cells, suggesting that elotuzumab can activate NK cells
through SLAMF7 binding. Elotuzumab facilitated
SLAMF7 interaction with EAT-2 and enhanced phos-
phorylation of ERK in NK cells, confirming a direct
role of elotuzumab on NK cell activation through
SLAMF7 ligation [16]. Interestingly, elotuzumab and
its F(ab’)2 fragment can stabilize the interaction be-
tween SLAMF7 on NK cells and MM cells and enhance
MM cell killing, again suggesting the presence of
elotuzumab-induced ADCC-independent cytotoxicity
of NK cells against MM cells [16]. Furthermore, Tai et
al. showed that elotuzumab can inhibit MM cell adhe-
sion to BMSCs and may overcome the stimulatory ef-
fects of BMSCs on MM growth and survival in co-
culture experiments [13], indicating that targeting
myeloma-microenvironment interaction is an add-
itional anti-myeloma mechanism of elotuzumab as
summarized above.
While initial xenograft studies have demonstrated
significant anti-myeloma activity of elotuzumab [7, 13],
combination of elotuzumab with other agents appeared
to have superior activities. Van Rhee and colleagues
showed that elotuzumab in combination with bortezo-
mib had better anti-tumor activity than either single
agent alone in an OPM2 xenograft model [17]. Similarly,
Balasa et al. demonstrated that adding lenalidomide
enhanced the anti-myeloma activity of elotuzumab in
the OPM2 xenograft model [18]. These studies pro-
vided the rationale for testing elotuzumab-containing
combinational therapy for MM in clinical trials.
Modulating NK cell-mediated ADCC by activating the
CD137 receptor with an agonistic antibody or block-
ing killer immunoglobulin-like receptor (KIR)-medi-
ated inhibitory signaling with lirilumab has been
shown to enhance the anti-myeloma activity of elotu-
zumab [19, 20]. Preliminary ex vivo studies have
shown that elotuzumab can enhance the cytotoxicity
of ex vivo expanded NK (ENK) cells towards MM cells
[21, 22]. These combinational immunotherapies
warrant further investigation.
Elotuzumab for MM treatment in clinical trials
Clinical trials of elotuzumab that have data reported are
summarized in Table 1. The first-in-human study of elo-
tuzumab was a phase 1 trial evaluating its safety, toler-
ability, pharmacokinetics, and pharmacodynamics [23].
Thirty-five patients with MM who had received at least
two lines of therapy were enrolled, with a median age of
64.5 years and a median of 4.5 lines of therapy. Using a
standard 3 + 3 dose escalation approach, 34 patients
were treated, with doses ranging from 0.5 to 20 mg/kg.
The maximum tolerated dose (MTD) was not reached
with dose escalation up to the maximum planned dose
(MPD). Common treatment-related adverse events (AEs)
included chills, fatigue, pyrexia, cough, headache,
anemia, nausea, and back pain, most of which were
grade 1–2. Only two grade 3–4 AEs were attributed to
elotuzumab, including one grade 3 hypersensitivity and
one grade 4 acute renal failure. Transfusion reactions
appeared common although most were grade 1–2, ne-
cessitating a protocol amendment to include premedica-
tion before first infusion. Commonly seen AE with other
anti-myeloma agents such as peripheral neuropathy with
bortezomib and thalidomide were not observed with elo-
tuzumab [24, 25]. SLAMF7 on bone marrow-derived
MM cells was saturated at doses of 10 and 20 mg/kg.
After a median of four infusions at 2-week intervals,
nine patients had stable disease (SD), but no objective
response was observed. However, it should be noted that
only three patients were treated at the dose that has
been FDA approved (10 mg/kg).
Subsequent clinical studies have focused on elotuzu-
mab in combination with other agents such as IMiDs
and PIs. In the phase 1b part of the 1703 study, elotuzu-
mab at escalating doses (5, 10, and 20 mg/kg) was com-
bined with lenalidomide and dexamethasone (Rd) for
treatment of relapsed or refractory (RR) MM [26].
Twenty-nine patients were enrolled, with a median age
of 60 and a median of 3 prior therapies. No dose-
limiting toxicity (DLT) was observed during dose escal-
ation, and the 20 mg/kg cohort was expanded. Common
AEs included fatigue, anemia, diarrhea, nausea, constipa-
tion, and neutropenia; most frequently reported grade
3–4 AEs were neutropenia (36 %) and thrombocytopenia
(21 %). Infusion reactions were observed in 89 % of the
patients, most of which were grade 1–2. In the updated
report, objective response rate (ORR) was 82 % for the
28 treated patients, with 1 (4 %) complete response
(CR), 12 (43 %) very good partial response (VGPR), and
10 (36 %) partial response (PR) [27]. For the 20 mg/kg
cohort (22 patients, treated until disease progression),
median duration of response (DOR) has not been reached
after a median follow-up of 16.4 months [26]. According
to the updated report, the median progression-free
survival (PFS) was 32.9 months overall [27].
Wang et al. Journal of Hematology & Oncology  (2016) 9:55 Page 3 of 8
The phase 2 part of the 1703 study evaluated elotuzu-
mab (10 or 20 mg/kg through randomization) in com-
bination with Rd for RR MM in 73 patients [27]. The
median age was 62, and patients had received 1–3 prior
lines of therapy. The median follow-up was 21.2 months
for the 10 mg/kg group (36 patients) and 16.8 months
for the 20 mg/kg group (37 patients). The overall ORR
was 84 %, with 3 (4 %) stringent CR, 7 (10 %) CR, 31
(42 %) VGPR and 20 (27 %) PR. The ORR was 92 and
76 % for the 10 and 20 mg/kg groups, respectively. The
median time to initial/best response was 1.0/2.8 months
for the 10 mg/kg group and 1.7/2.4 months for the
20 mg/kg group. The median DOR was 34.8 and
29 months for the 10 and 20 mg/kg groups, respectively.
The median time to progression (TTP) or death was
32.5 and 25.0 months for the 10 and 20 mg/kg groups,
respectively, and 28.6 months overall. The safety profiles
were similar between the two groups. The most com-
mon grade 3–4 AE was cytopenia. Implementation of
a premedication regimen significantly reduced infusion
reaction occurrence to 11 % of the patients (mostly
grade 1–2).
Compared with historical data on Rd [28–31], the
1703 study demonstrated that addition of elotuzumab
improved the ORR (84 vs. 48–67 %) and PFS (28.6 vs.
11–18 months) in patients with RR MM [27]. The
ELOQUENT-2 study directly compared the efficacy of
elotuzumab plus Rd versus Rd alone for RR MM [32].
Based on results of the 1703 study, the dose of elotuzu-
mab in this phase 3 randomized trial was 10 mg/kg. In
total, 646 patients were enrolled, with a median age of
66 and a median of 2 prior therapies. Seventy percent of
patients had received bortezomib before, and 48 and 6 %
of patients had prior exposure to thalidomide and lenali-
domide, respectively. About one third of patients had
17p deletion. The median follow-up was 24.5 months.
The ORR was 79 % for the elotuzumab group (321 pa-
tients) and 66 % for the control group (325 patients)
(odds ratio 1.9). The PFS rate was 68 vs. 57 % for the
elotuzumab and control groups at 1 year and 41 vs. 27 %
at 2 years. The median PFS was 19.4 vs. 14.9 months for
the elotuzumab and control groups (hazard ratio 0.70).
The ORR and PFS in the elotuzumab group appeared in-
ferior to those in the 1703 study, but it should be noted
that patients in this trial were older, and more patients
had high-risk cytogenetic profiles and coexisting illnesses
[27, 32]. Cytopenias were the most common grade 3–4
AEs and occurred at similar rates in both groups, except
for a higher rate of lymphocytopenia in the elotuzumab
group (77 vs. 49 %), which was likely due to lymphocyte
trafficking. With mandatory premedication, infusion re-
action occurrence was 10 % in the elotuzumab group.
Results of the ELOQUENT-2 study clearly proved the
benefit of adding elotuzumab to Rd for the treatment of
RR MM. Based on these data, FDA approved elotuzu-
mab to be used in combination with lenalidomide and
dexamethasone for MM patients who had received one
to three prior therapies.
The ELOQUENT-1 trial, which studies Rd with or
without elotuzumab for untreated MM, is currently
Table 1 Major clinical trials of elotuzumab that have published data
Study NCT number (trial name) Phase N Regimen ORR PFS rate Median PFS
(months)
Zonder 2012 [23] NCT00425347
(HuLuc63-1701)
1 35a Elotuzumab (0.5–20 mg/kg) 0 – –
Lonial 2012 [26, 27] NCT00742560
(HuLuc63-1703)
1b 29b Elotuzumab (5–20 mg/kg) + Rd 82 % – 32.9
Richardson 2015 [27] NCT00742560
(HuLuc63-1703)
2 36 Elotuzumab (10 mg/kg) + Rd 92 % 32.5c
37 Elotuzumab (20 mg/kg) + Rd 76 % 25.0c
Lonial 2015 [32] NCT01239797
(ELOQUENT-2)
3 321 Elotuzumab (10 mg/kg) + Rd 79 % 1-year 68 %, 2-year 41 % 19.4
325 Rd 66 % 1-year 57 %, 2-year 27 % 14.9
Mateos 2014 [34] NCT01632150 2 40 Elotuzumab (10 mg/kg) + TDd 40 % – –
Jakubowiak 2012 [35] NCT00726869
(HuLuc63-1702)
1 28 Elotuzumab (2.5–20 mg/kg) + V 48 % 9.46e
Palumbo 2015 [38]
Jakubowiak 2016 [39]
NCT01478048 1/2 77f Elotuzumab (10 mg/kg) + VD 66 % 1-year 39 %, 2-year 18 % 9.7
75 VD 63 % 1-year 33 %, 2-year 11 % 6.9
N number; ORR objective response rate; PFS progression-free survival; Rd lenolidomide and dexamethasone; TD thalidomide and dexamethasone; V bortezomib;
VD bortezomib and dexamethasone
aThirty-four patients treated
bTwenty-eight patients treated
cMedian time to progression or death
dCyclophosphamide was added if progressing between cycle 2 and 5 or not responding by cycle 5
eMedian time to progression
fSeventy-five patients treated
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ongoing. A recent phase 1b trial studied the pharma-
cokinetics and safety of the elotuzumab plus Rd com-
bination in 26 patients with various renal function and
demonstrated that patients with severe renal impair-
ment (creatinine clearance [CrCl] < 30 mL/min, not
requiring dialysis) and end-stage renal disease (requir-
ing dialysis) had identical elotuzumab pharmacokinet-
ics and safety profile compared with patients with
normal renal function (CrCl > 90 mL/min), suggesting
that elotuzumab does not require dose adjustment in
MM patients with renal dysfunction [33]. The combin-
ation of elotuzumab with another IMiD, thalidomide,
was studied in a phase 2 trial [34]. Forty patients were
enrolled, with a median age of 64 and a median of 3
prior therapies. Patients received elotuzumab in com-
bination with thalidomide and dexamethasone (TD)
and cyclophosphamide if progressing between cycle 2
and 5 or not responding by cycle 5. Except for infusion
reactions, elotuzumab caused minimal incremental
toxicity when added to TD. The ORR was 40 %, and
63 % of patients maintained response at 1 year.
The combination of elotuzumab and PIs has also
been studied. A phase 1 trial studied the elotuzumab
and bortezomib combination for patients with RR MM
[35]. Twenty-eight patients with a median age of 63
and a median of 2 prior therapies were enrolled. During
elotuzumab dose escalation (2.5 to 20 mg/kg), no DLT
was observed and MTD was not reached up to MPD.
The most frequent grade 3–4 AEs were lymphopenia
and fatigue. In 27 evaluable patients, the ORR was
48 %. The median TTP was 9.46 months. Compared
with previous data on bortezomib monotherapy for RR
MM [3, 36, 37], the elotuzumab plus bortezomib com-
bination appeared to have better ORR (48 vs. 27-41 %)
Table 2 Major ongoing clinical trials of elotuzumab
NCT number Title Ph N Recruitment
NCT01335399 (ELOQUENT-1) Phase III study of lenalidomide and dexamethasone with or without elotuzumab
to treat newly diagnosed, previously untreated multiple myeloma
3 750 Active, not recruiting
NCT02272803 Phase II study of lenalidomide/dexamethasone with or without elotuzumab for
newly diagnosed MM patients in Japan
2 80 Recruiting
NCT01241292 Japanese study of BMS-901608 (Elotuzumab) in combination with lenalidomide
and low dose dexamethasone
1 7 Active, not recruiting
NCT02159365 Study of safety of elotuzumab administered over approximately 60 min in
combination with lenalidomide and dexamethasone for newly diagnosed or
relapsed/refractory multiple myeloma patients
2 76 Active, not recruiting
NCT01393964 Study of elotuzumab in combination with lenalidomide and dexamethasone in
subjects with multiple myeloma and various levels of renal function
1 35 Active, not recruiting
NCT02279394 Trial of combination of elotuzumab and lenalidomide +/− dexamethasone in
high-risk smoldering multiple myeloma
2 82 Recruiting
NCT02420860 Study of elotuzumab with lenalidomide as maintenance after autologous stem
cell transplant (ASCT)
2 100 Recruiting
NCT02655458 Elotuzumab in autologous stem cell transplantation (ASCT) and lenalidomide
maintenance for multiple myeloma
1 15 Recruiting
NCT02612779 A study of elotuzumab in combination with pomalidomide and low dose
dexamethasone (EPd) in patients with multiple myeloma relapsed or
refractory to prior treatment with lenalidomide
2 60 Recruiting
NCT02654132 Trial of pomalidomide and low-dose dexamethasone with or without elotuzumab
to treat refractory and relapsed and refractory multiple myeloma (ELOQUENT-3)
2 121 Recruiting
NCT01668719 (S1211) Bortezomib, dexamethasone, and lenalidomide with or without elotuzumab in
treating patients with newly diagnosed high-risk multiple myeloma
1/2 122 Recruiting
NCT02375555 Study of bortezomib, lenalidomide, dexamethasone & elotuzumab in newly
diagnosed MM
2 40 Recruiting
NCT02495922 (GMMG HD6) A phase III trial on the effect of elotuzumab in VRD induction/consolidation
and lenalidomide maintenance in patients with newly diagnosed myeloma
3 516 Recruiting
NCT02718833 A study of elotuzumab with pomalidomide, bortezomib, and dexamethasone in
relapsed multiple myeloma
2 46 Recruiting
NCT02726581 Study of combinations of nivolumab, elotuzumab, pomalidomide and
dexamethasone in multiple myeloma
3 406 Recruiting
NCT02252263 A phase I open label study of the safety and tolerability of elotuzumab
(BMS-901608) administered in combination with either lirilumab (BMS-986015)
or urelumab (BMS-663513) in subjects with multiple myeloma
1 136 Active, not recruiting
Ph phase; N number
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and TTP (9.46 vs. 6.22–7 months). A phase 2 random-
ized trial compared elotuzumab in combination with
bortezomib and dexamethasone (Vel/Dex) vs. Vel/Dex
alone for patients with RR MM [38, 39]. In total, 152
patients were randomized, with a median age of 66.
The ORR was 66 % in the elotuzumab arm (77 patients)
and 63 % in the control arm (75 patients). The 1-year
PFS rate was 39 and 33 %, and 2-year PFS rate was 18
and 11 %, for the elotuzumab and control arm, respect-
ively. The median PFS was 9.7 months in the elotuzu-
mab arm and 6.9 months in the control arm. The PFS
rates were lower and the PFS was shorter than those
seen in the ELOQUENT-2 study in which Rd was used
[32]. Nevertheless, data from this phase 2 study suggest
that addition of elotuzumab to bortezomib-based
therapy may provide additional benefit for patients with
RR MM.
Adding elotuzumab to the IMiD/PI combination is
also under investigation. The SWOG study S1211 was
designed to evaluate the efficacy of adding elotuzumab
to lenalidomide, bortezomib, and dexamethasone
(RVd) for the front line therapy of high risk MM. In
the phase 1 portion, newly diagnosed symptomatic
MM patients regardless of risk were eligible. Eight pa-
tients were enrolled and six received treatment. At the
time of report, all six patients had completed 8 cycles
of induction therapy with elotuzumab in combination
with RVd, and five had completed at least 4 cycles of
maintenance therapy with dose-attenuated RVd and
elotuzumab. The phase 1 safety data demonstrated
that elotuzumab did not lead to major additive AEs
beyond those known for RVd [40]. The phase 2 part of
the trial is ongoing and will provide the efficacy data.
Some additional ongoing trials of elotuzumab in com-
bination with IMiDs, PIs and/or other novel agents
are listed in Table 2.
Conclusions
Elotuzumab has demonstrated excellent efficacy and
safety profiles when combined with an IMiD or PI for
the treatment of RR MM. There was only limited data
on single agent elotuzumab for RR MM, with only
three patients treated at the FDA approved dose in the
initial phase 1 study [23]. Further investigations
should be done to evaluate its efficacy when used
alone. Ongoing clinical trials will further define the ef-
ficacy of elotuzumab with IMiD or PI combinations in
both untreated and RR MM patients and evaluate the
four drug combination (elotuzumab, IMiD, PI, and
corticosteroid) for MM treatment. Importantly, so far,
there has been no data demonstrating the efficacy of
elotuzumab in lenalidomide-refractory patients. How
to overcome this significant limitation requires further
investigation. The use of elotuzumab as part of induction
and/or maintenance therapy is under investigation.
Whether combining elotuzumab with chemotherapy is
beneficial in MM needs to be studied. Combining
elotuzumab with daratumumab is worth investigating.
Hitting CD38 and SLAMF7 simultaneously may
provide a higher MM cell killing efficacy and may over-
come potential resistance to either agent. Daratumu-
mab reduces NK cell levels, and perhaps combining
daratumumab with elotuzumab may be effective in
overcoming this effect. Combining elotuzumab with
other immunotherapies such as anti-PD1 antibodies,
anti-KIR antibodies, and CD137 agonizing antibodies
are under investigation in clinical trials already. Anti-
PD1 therapies may activate T cell-mediated MM cell
killing mechanisms, adding to the NK cell-mediated
anti-myeloma activities. Activating the CD137 receptor
or blocking the KIR-mediated inhibitory signaling can
modulate NK cell-mediated ADCC, and combining elo-
tuzumab with these agents may lead to enhanced MM
cell killing by ADCC [19, 20]. With expanding options
available, when and how to use each agent will be an
ever-evolving question. Related biomarkers on response
and prognosis are to be studied. Whether elotuzumab,
alone or in combination with other regimens, provides
a different efficacy and safety profile in a specific popu-
lation requires further study [30, 41].
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